An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys

Journal of Neuroscience Methods

Volumn 183, Issue 2, 2009, Pages 188-194

  Liu, N ^a   Yue, F ^a   Tang, W P ^b   Chan, P ^a  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b Wincon Theracells Biotechnologies Inc   (China)

Author keywords

Cynomolgus monkey; MPTP; Parkinson's disease; Video image analysis system

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BODY EQUILIBRIUM; BODY MOVEMENT; BODY POSTURE; BRADYKINESIA; CONTROLLED STUDY; DEFENSIVE BEHAVIOR; DISEASE MODEL; FREEZING; GAIT; IMAGE ANALYSIS; LOCOMOTION; MALE; MONKEY; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RATING SCALE; TIME; TREMOR; VIDEORECORDING;

ANIMALS; DISEASE MODELS, ANIMAL; FREEZING REACTION, CATALEPTIC; FUNCTIONAL LATERALITY; GAIT DISORDERS, NEUROLOGIC; GENETIC TESTING; LINEAR MODELS; LOCOMOTION; MACACA FASCICULARIS; MALE; MOVEMENT; PARKINSONIAN DISORDERS; ROC CURVE; VIDEO RECORDING;

EID: 70049100367     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2009.06.037     Document Type: Article

References (18)

1. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., and Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sci 39 (1986) 7-16
2. Bove J., Prou D., Perier C., and Przedborski S. Toxin-induced models of Parkinson's disease. NeuroRx 2 (2005) 484-494
3. Chassain C., Eschalier A., and Durif F. Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. J. Neurosci Methods 111 (2001) 9-16
4. Emborg M.E., Ma S.Y., Mufson E.J., Levey A.I., Taylor M.D., Douglas Brown W., et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401 (1998) 253-265
5. Emborg M.E., Shin P., Roitberg B., Sramek J.G., Chu Y., Stebbins G.T., et al. Systemic administration of the immunophilin ligand GPI 1046 in MPTP-treated monkeys. Exp Neurol 168 (2001) 171-182
6. Emborg M.E. Nonhuman primate models of Parkinson's disease. ILAR J 48 (2007) 339-355
7. Hoehn M.M., and Yahr M.D. Parkinsonism: onset, progression, and mortality, 1967. Neurology 50 (1998) 318-334
8. Jordan S., Eberling J.L., Bankiewicz K.S., Rosenberg D., Coxson P.G., VanBrocklin H.F., et al. Brain Res 750 (1997) 264-276
9. Kurlan R., Kim M.H., and Gash D.M. Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 6 (1991) 111-118
10. Lang A.E., and Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med 339 (1998) 1044-1053
11. Moussaoui S., Obinu M.C., Daniel N., Reibaud M., Blanchard V., and Imperato A. The antioxidant Ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease. Exp Neurol 166 (2000) 235-245
12. Nomoto M., Stahl S., Jenner P., and Marsden C.D. Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset. Mov Disord 2 (1987) 37-45
13. Obinu M.C., Reibaud M., Blanchard V., Moussaoui Saliha, and Imperato A. Neuroprotective effect of riluzole in a primate model of Parkinson's disease: behavioral and histological evidence. Mov Disord 17 (2002) 13-19
14. Ovadia A., Zhang Z., and Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol Aging 16 (1995) 931-937
15. Russ H., Mihatsch W., Gerlach M., Riederer P., and Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease?. Neurosci Lett 123 (1991) 115-118
16. Shneider J.S., Decamp E., and Wade T. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J Neurosci 19 (1999) 6643-6649
17. Smith L.A., Jackson M.J., Hansard M.J., Maratos E., and Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 18 (2003) 487-495
18. Stanley Burns R., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., and Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80 (1983) 4546-4550